The IP Litigation team secured a unanimous verdict for Insulet Corporation in a trade secret misappropriation case against EOFlow Co. (Insulet Corporation v. EOFlow Co., Ltd., et al) concerning multiple trade secrets owned by Insulet relating to Insulet’s insulin patch pump, the Omnipod. The jury found that EOFlow and its CEO misappropriated four of Insulet’s trade secrets, awarding Insulet $170 million in compensatory damages. The jury also found that the misappropriation of three of Insulet’s trade secrets was willful and malicious and awarded an additional $282 million in exemplary or punitive damages, for a total damages award of $452 million. Insulet also sought and obtained nominal damages of $1 per trade secret for the misappropriation by two of its former employees.
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.
The Goodwin team was led by Robert Carroll, Robert Frederickson, and Alexandra Valenti with assistance from Alexandra Lu, Scott Bluni, James Breen, Jenny Zhang, Timothy Keegan, Danit Maor, William Evans, Matthew Ginther, Arsh Raince, Shweta Rao, with paralegal help from Albert Lessard, and Alison Fitzgerald; and case assistance from Sophie Scola.